MHRA Appoints Jason Bonander to Lead Digital Systems
In a government announcement, the MHRA said Jason Bonander will become its new Chief Digital and Technology Officer in late May 2026. He is joining from the US Centers for Disease Control and Prevention, where he served as Chief Information Officer. On paper, that can look like a specialist staffing update. In practice, it is a story about how the UK keeps medicines and medical devices safe. If you only hear about regulators when something goes wrong, that is normal. Most of their work sits in the background. But who runs their digital systems matters, because those systems help officials review evidence, track safety concerns, share information and explain decisions to the public.
According to the MHRA's own notes, the agency regulates medicines and medical devices across the UK and checks that they work and are acceptably safe. It is an executive agency of the Department of Health and Social Care. That means it is one of the public bodies helping decide whether a treatment, test or device should be trusted for use. **What 'acceptably safe' means:** no medicine or device is completely risk-free. Regulation is about weighing benefit against harm, setting standards, and then keeping watch after products reach patients. If you use an inhaler, a hearing aid or a home test kit, this kind of quiet oversight affects you even if you never notice it.
This is where the digital job becomes important. Modern regulation does not run on paper files alone. It depends on secure technology, reliable data, cyber protection and systems that let experts spot patterns quickly. If reports of side effects are hard to collect or compare, safety action can slow down. If systems are clear and well built, a regulator can respond sooner and explain itself better. The MHRA says it wants regulation that is faster, more efficient and more transparent. It also says it wants to use data to regulate medicines, AI and advanced technologies. That sounds technical, but the public question is simple: can the agency keep up with new products without lowering the standard patients deserve?
Bonander arrives with a background that fits that challenge. The MHRA says he brings more than 25 years of technology leadership and health informatics experience. At the CDC, he led technology and cyber-security operations as well as public health informatics and data-sharing work. Those are not small tasks. They involve running systems that have to work under pressure and still protect sensitive information. For the MHRA, that sort of experience matters because regulation now relies on both scientific judgement and digital competence. You need people who understand databases, security, service design and public health at the same time. A regulator cannot promise smarter oversight if its own systems are outdated or difficult to use.
In statements released with the announcement, MHRA chair Professor Anthony Harnden and chief executive Lawrence Tallon both presented the appointment as part of a wider push to modernise the agency ahead of a new five-year strategy. Their message was clear: better digital tools should help protect patients and make regulation more responsive. That is the promise. The test will be whether ordinary people see the benefit. Better systems should make it easier to report problems, clearer to understand decisions and quicker to identify risks. Speed on its own is not enough. In health regulation, faster only counts as progress if public trust and safety stay in place.
**What this means for you:** this is not really just a story about one senior hire. It is a reminder that the software, data systems and security rules behind public health bodies shape what happens in clinics, pharmacies and homes. When those systems improve, patients can be better protected. When they fail, the damage can spread quietly before most people even realise there is a problem. As the MHRA prepares its next strategy, this appointment suggests digital regulation will sit close to the front of its plans for medicines, medical devices and newer technologies. For you, the takeaway is straightforward: leadership changes in public agencies may sound distant, but they can affect how safely and fairly health products are checked before they reach everyday life.